Shares of Novavax, Inc. (NASDAQ:NVAX) ended Tuesday session in red amid volatile trading. The shares closed down -0.02 points or -1.36% at $1.45 with 5.27 million shares getting traded. Post opening the session at $1.49, the shares hit an intraday low of $1.41 and an intraday high of $1.50 and the price vacillated in this range throughout the day. The company has a market cap of $391.87 million and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, in addition to pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, in addition to combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) ended Tuesday session in green amid volatile trading. The shares closed up +0.54 points or 1.03% at $53.16 with 10.09 million shares getting traded. Post opening the session at $52.29, the shares hit an intraday low of $52.02 and an intraday high of $53.34 and the price vacillated in this range throughout the day. The company has a market cap of $91.65 billion and the numbers of outstanding shares have been calculated to be 1.67 billion shares.
Bristol-Myers Squibb Co (BMY) recently declared new data presentations from studies evaluating Opdivo (nivolumab) as monotherapy or in combination with Yervoy (ipilimumab) in the treatment of melanoma, counting new research on the efficacy and safety of the combination in melanoma patients with high unmet need counting those with elevated serum lactate dehydrogenase (LDH) and brain metastases. Additional presentations will also highlight new data on health economics and real-world outcomes in patients living with the disease.
The data, to be presented at the Society for Melanoma Research (SMR) 2016 Congress in Boston, MA from November 6-9, underscore the Company’s continued leadership in advancing melanoma treatment research and deepening our scientific understanding of the potential of Immuno-Oncology as a treatment option counting the potential survival impact of combination therapies.